NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: C000000342

Registered date:01/03/2006

Japan Antiphospholipid syndrome-Stroke Prevention Study

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedAntiphospholipid syndrome
Date of first enrollment2006/03/31
Target sample size100
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Warfarin, INR 2.0, 2 years cilostazol, 200mg/day, 2 years or ticlopidine, 100-200mg/day, 2 years

Outcome(s)

Primary OutcomeCerebral Infarct Score in MRI
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteriaFemale patients who are pregnant or plans to be pregnant Patients who cannot have warfarin or antiplatetet drugs Patients who are required to take warfarin Patients with severe hepatic, renal or cardiac failure Other inadequate patients for this clinical trial

Related Information

Contact

public contact
Name Tatsuya Atsumi
Address N14 W5, Kita-ku, Sapporo Japan
Telephone 011-706-5915
E-mail at3tat@med.hokudai.ac.jp
Affiliation Hokkaido University Hospital Medicine II
scientific contact
Name Tatsuya Atsumi
Address N14 W5, Kita-ku, Sapporo Japan
Telephone 011-706-5915
E-mail
Affiliation Hokkaido University Hospital Medicine II